A new drug application has been filed with the FDA for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.
The FDA has granted a priority review to a new drug application for duvelisib for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and an accelerated approval for the treatment of patients with relapsed/refractory follicular lymphoma.
Alan Skarbnik, MD, shares his insight on the latest updates in chronic lymphocytic leukemia presented at the 2017 ASH Annual Meeting.
The FDA has granted a priority review to moxetumomab pasudotox for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy.
Molecular minimal residual disease was associated with a higher rate of relapse and a lower rate of relapse-free survival and overall survival for patients with newly-diagnosed acute myeloid leukemia.
Older patients with active, relapsed, or refractory acute myeloid leukemia have a low survival rate, very poor risk assessments, and limited therapeutic options, with conventional care consisting primarily of salvage chemotherapy.
Stuart L. Goldberg, MD, discusses the management of patients with acute myeloid leukemia as well as those with myelodysplastic syndrome.
The FDA has approved blinatumomab for the treatment of patients with minimal residual disease–positive B-cell precursor acute lymphoblastic leukemia.
Ponatinib maintained deep, durable responses in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CP-CML).
The regimen of venetoclax (Venclexta) plus rituximab (Rituxan) lowered the risk of disease progression or death by 83% versus bendamustine (Treanda) plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.